NHANES 1999–2018 CKD adults (n=3965) showed 1163 deaths; RAR quartiles ranged from <2.93 to ≥3.45, enabling population-level ...

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, ...

At the Community Oncology Alliance Payer Exchange & Innovation Summit in September, a panel of statistical experts posed a ...

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote ...

Once-weekly retatrutide reduced body weight by an average of 20.8% at the highest dose and lowered hemoglobin A 1C (HbA 1C) ...

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year ...

Weighted average monthly Medicare Advantage (MA) premiums are projected to fall 16.5% in 2027, while average premiums for ...

Any weekend catch-up sleep was independently associated with lower OAB odds (adjusted OR 0.79; 95% CI 0.67–0.93) after ...

Open-source oncology tools span patient-facing trackers and explainers, genomics-to-therapy ranking systems, and LLMs ...

Before defining a network meta-analysis, Dr. Citrome walks through the statistical fundamentals that make one useful. He ...

Incremental outcomes favored tirzepatide (4.46 QALYs; $190,270) and semaglutide (3.04 QALYs; $243,094) versus resmetirom (3.47 QALYs; $948,743), driving large ICER separation.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.